Back

Akeso secures Phase I clearance for EGFR/TROP2 bispecific ADC AK158D1

Verifying
  • Akeso secured Phase I trial clearance for AK158D1, an EGFR/TROP2 bispecific ADC.
  • AK158D1 is Akeso's fourth ADC and second bispecific ADC entering clinical development.
  • The trial will assess AK158D1 in patients with advanced malignant solid tumors.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.